Faeth Therapeutics, Inc.
FTHHealthcare|Biotechnology|US
$22.05
+2.13 (+10.69%)
DCF Value
$5.16
Tangible Book / Share
$6.50
Cash / Share
$6.76
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07558733 Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer | HR+ HER2- Breast Cancer | P1P2 | Recruiting | 32 | Open-label | Serabelisib, Sapanisertib, Fulvestrant |
| NCT06463028 Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | Endometrial Cancer | P2 | Recruiting | 40 | Open-label | Sapanisertib, Serabelisib, Paclitaxel |
| NCT05275673 A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer | P2 | Terminated | 7 | RCT, Open-label | sapanisertib |
| NCT05300048 Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | Advanced Solid Tumor, PIK3CA Mutation | P1 | Terminated | 34 | Open-label | Serabelisib, Nab paclitaxel |
| NCT05183295 Medical Food for the Dietary Management of Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | N/A | Withdrawn | — | Open-label | — |
| NCT05078775 Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma | N/A | Completed | 39 | Open-label | — |